StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Call
StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Call
Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) ("StageZero" or the "Company") today announced that it will host a conference call as part of its Special and Annual General Meeting of Shareholders on Wednesday June 7, 2023, so that all shareholders may follow along with the proceedings of the meeting.
安大略省多伦多-(Newsfile Corp.-2023年6月5日)-StageZero生命科学有限公司(多伦多证券交易所股票代码：SZLS)(以下简称“StageZero”或“公司”)今天宣布，将于2023年6月7日(星期三)召开一次电话会议，作为股东特别大会和年度股东大会的一部分，以便所有股东都能关注会议的进程。
Annual General and Special Meeting Conference Call
年度大会和特别会议电话会议
Event Date: Wednesday June 7, 2023
Time: 2:00pm ET
Webcast Link:
活动日期时间：2023年6月7日星期三
时间：美国东部时间下午2：00
网络直播链接：
Conference Call Numbers
电话会议号码
Canada/USA TF: 1-800-319-4610
Toronto Toll: +1-416-915-3239
International Toll: +1-604-638-5340
加拿大/美国电话：1-800-319-4610
多伦多通行费：+1-416-915-3239
国际通行费：+1-604-638-5340
About StageZero Life Sciences, Ltd.
StageZero生命科学有限公司简介
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telehealth program that provides clinical interventions to help patients reduce the risk of developing late-stage disease (AVRT).
StageZero生命科学有限公司是一家垂直整合的医疗保健公司，致力于通过下一代诊断和独特的远程医疗计划来改善癌症和其他慢性病的早期检测和管理，该计划提供临床干预措施，帮助患者降低发展为晚期疾病(AVRT)的风险。
The Company's next generation test, Aristotle, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
该公司的下一代测试亚里士多德是有史以来第一个同时从单一血液样本中筛查多种癌症的信使核糖核酸多癌症小组，对每种癌症都具有高度的敏感性和特异性。亚里士多德使用信使核糖核酸技术来识别多种癌症类型的分子特征，并建立在该公司的专利技术平台哨兵原理的基础上。这项潜在的技术已经在9000多名患者中得到验证，并在北美被10万多名患者使用。
Aristotle is processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company provides patients with multiple clinical programs, for risk management and treatment, through its subsidiary Care Oncology.
亚里士多德在该公司的临床实验室StageZero生命科学公司进行处理，StageZero生命科学公司是位于弗吉尼亚州里士满的CAP认证和CLIA认证的高复杂性参考实验室。此外，该公司通过其子公司Care Oncology为患者提供多种临床项目，用于风险管理和治疗。
StageZero Life Sciences, Ltd. trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
StageZero生命科学有限公司在多伦多证券交易所的交易代码为SZLS，在OTCQB的交易代码为SZLSF。
For further information please contact:
欲了解更多信息，请联系：
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
投资者关系
丽贝卡·格雷科
1-855-420-7140分机1838年
邮箱：rgreco@stagezerols.com
To view the source version of this press release, please visit
要查看本新闻稿的源版本，请访问